50870-44-5

Basic information

• Product Name: 1-(4-BroMo-3-Methoxyphenyl)ethanone
• Synonyms: 1-(4-BroMo-3-Methoxyphenyl)ethanone;1-(4-bromo-3-methoxyphenyl)ethan-1-one
• CAS NO: 50870-44-5
• Molecular Formula: C₉H₉BrO₂
• Molecular Weight: 229.07056
• Mol File: 50870-44-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 31.5-32.0 °C
• Boiling Point: 292.7±25.0 °C(Predicted)
• Appearance: /
• Density: 1.421±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 1-(4-BroMo-3-Methoxyphenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BroMo-3-Methoxyphenyl)ethanone(50870-44-5)
• EPA Substance Registry System: 1-(4-BroMo-3-Methoxyphenyl)ethanone(50870-44-5)

Safety Data

• Hazardous Substances Data: 50870-44-5(Hazardous Substances Data)

Usage

General Description

1-(4-Bromo-3-methoxyphenyl)ethanone is a chemical compound with the molecular formula C9H9BrO2. It is a ketone with a benzene ring substituted with a bromine atom at the 4 position and a methoxy group at the 3 position. 1-(4-BroMo-3-Methoxyphenyl)ethanone is commonly used in organic synthesis and pharmaceutical research as a building block for creating various pharmaceuticals and bioactive molecules. It may also have potential applications in the field of medicinal chemistry, particularly in the development of new drugs for treating various diseases and conditions. Additionally, 1-(4-Bromo-3-methoxyphenyl)ethanone may also be used in research and development of crop protection products in the agricultural industry.

Upstream product

• 56256-15-6 4-bromo-3-methoxy-benzoyl chloride 
• 917-54-4 methyllithium 
• 19056-40-7 4-bromo-3-methoxyaniline 
• 127-09-3 sodium acetate 

Downstream Products

• 56256-14-5 4-bromo-3-methoxy-benzoic acid 
• 1402448-65-0 2,4,6-tris(3-methoxy-4-bromophenyl)pyridine 

Relevant articles and documents

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

Structure-based approach to the development of potent and selective inhibitors of dihydrofolate reductase from Cryptosporidium

Cryptosporidiosis is an emerging infectious disease that can be life-threatening in an immune-compromised individual and causes gastrointestinal distress lasting up to 2 weeks in an immune-competent individual. There are few therapeutics available for eff